Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Forte Biosciences management to meet virtually with B. Riley Securities » 04:55
11/25/20
11/25
04:55
11/25/20
04:55
FBRX

Forte Biosciences

$37.10 /

-2.78 (-6.97%)

Virtual Meetings to be…

Virtual Meetings to be held November 23-25 hosted by B. Riley Securities.

ShowHide Related Items >><<
FBRX Forte Biosciences
$37.10 /

-2.78 (-6.97%)

FBRX Forte Biosciences
$37.10 /

-2.78 (-6.97%)

11/11/20 Chardan
Forte Biosciences price target raised to $115 from $110 at Chardan
09/24/20 Chardan
Forte Biosciences price target raised to $110 from $60 at Chardan
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
09/10/20 Chardan
Forte Biosciences price target raised to $60 from $45 at Chardan
  • 29
    Oct
FBRX Forte Biosciences
$37.10 /

-2.78 (-6.97%)

FBRX Forte Biosciences
$37.10 /

-2.78 (-6.97%)

Conference/Events
Forte Biosciences management to meet virtually with B. Riley Securities » 05:55
11/24/20
11/24
05:55
11/24/20
05:55
FBRX

Forte Biosciences

$39.96 /

-0.01 (-0.03%)

Virtual Meetings to be…

Virtual Meetings to be held November 23-25 hosted by B. Riley Securities.

ShowHide Related Items >><<
FBRX Forte Biosciences
$39.96 /

-0.01 (-0.03%)

FBRX Forte Biosciences
$39.96 /

-0.01 (-0.03%)

11/11/20 Chardan
Forte Biosciences price target raised to $115 from $110 at Chardan
09/24/20 Chardan
Forte Biosciences price target raised to $110 from $60 at Chardan
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
09/10/20 Chardan
Forte Biosciences price target raised to $60 from $45 at Chardan
  • 29
    Oct
FBRX Forte Biosciences
$39.96 /

-0.01 (-0.03%)

FBRX Forte Biosciences
$39.96 /

-0.01 (-0.03%)

Conference/Events
Forte Biosciences management to meet virtually with B. Riley Securities » 04:55
11/23/20
11/23
04:55
11/23/20
04:55
FBRX

Forte Biosciences

$40.55 /

+1.43 (+3.66%)

Virtual Meetings to be…

Virtual Meetings to be held November 23-25 hosted by B. Riley Securities.

ShowHide Related Items >><<
FBRX Forte Biosciences
$40.55 /

+1.43 (+3.66%)

FBRX Forte Biosciences
$40.55 /

+1.43 (+3.66%)

11/11/20 Chardan
Forte Biosciences price target raised to $115 from $110 at Chardan
09/24/20 Chardan
Forte Biosciences price target raised to $110 from $60 at Chardan
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
09/10/20 Chardan
Forte Biosciences price target raised to $60 from $45 at Chardan
  • 29
    Oct
FBRX Forte Biosciences
$40.55 /

+1.43 (+3.66%)

FBRX Forte Biosciences
$40.55 /

+1.43 (+3.66%)

Conference/Events
Forte Biosciences management to meet virtually with B. Riley Securities » 12:07
11/20/20
11/20
12:07
11/20/20
12:07
FBRX

Forte Biosciences

$39.38 /

+0.26 (+0.66%)

Virtual Meetings to be…

Virtual Meetings to be held November 23-25 hosted by B. Riley Securities.

ShowHide Related Items >><<
FBRX Forte Biosciences
$39.38 /

+0.26 (+0.66%)

FBRX Forte Biosciences
$39.38 /

+0.26 (+0.66%)

11/11/20 Chardan
Forte Biosciences price target raised to $115 from $110 at Chardan
09/24/20 Chardan
Forte Biosciences price target raised to $110 from $60 at Chardan
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
09/10/20 Chardan
Forte Biosciences price target raised to $60 from $45 at Chardan
  • 29
    Oct
FBRX Forte Biosciences
$39.38 /

+0.26 (+0.66%)

FBRX Forte Biosciences
$39.38 /

+0.26 (+0.66%)

Recommendations
Forte Biosciences price target raised to $115 from $110 at Chardan » 08:05
11/11/20
11/11
08:05
11/11/20
08:05
FBRX

Forte Biosciences

$34.44 /

+0.07 (+0.20%)

Chardan analyst Gbola…

Chardan analyst Gbola Amusa raised the firm's price target on Forte Biosciences to $115 from $110 and reiterates a Buy rating on the shares following the company's Q3 results. Forte remains on track to generate phase II data by mid-2021, Amusa tells investors in a research note. A positive Phase II result for FB-401 in 2021, if consistent with FB-401's prior phase I/IIa published data, would prove to the one of the most important readouts for a mid-stage biotech company in 2021, and would catalyze performance of the entire microbiome medicines space, with "considerably more upside" for Forte, says the analyst.

ShowHide Related Items >><<
FBRX Forte Biosciences
$34.44 /

+0.07 (+0.20%)

FBRX Forte Biosciences
$34.44 /

+0.07 (+0.20%)

09/24/20 Chardan
Forte Biosciences price target raised to $110 from $60 at Chardan
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
09/10/20 Chardan
Forte Biosciences price target raised to $60 from $45 at Chardan
08/28/20 Chardan
Forte Biosciences upgraded to Buy from Neutral at Chardan
  • 29
    Oct
FBRX Forte Biosciences
$34.44 /

+0.07 (+0.20%)

FBRX Forte Biosciences
$34.44 /

+0.07 (+0.20%)

Over a month ago
Syndicate
Forte Biosciences 1.404M share Spot Secondary priced at $28.50 » 08:08
10/29/20
10/29
08:08
10/29/20
08:08
FBRX

Forte Biosciences

$29.43 /

-4.14 (-12.33%)

The deal size was…

The deal size was increased to $40M in common stock from $30M in common stock. Ladenburg, Truist and Chardan acted as joint book running managers for the offering.

ShowHide Related Items >><<
FBRX Forte Biosciences
$29.43 /

-4.14 (-12.33%)

FBRX Forte Biosciences
$29.43 /

-4.14 (-12.33%)

09/24/20 Chardan
Forte Biosciences price target raised to $110 from $60 at Chardan
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
09/10/20 Chardan
Forte Biosciences price target raised to $60 from $45 at Chardan
08/28/20 Chardan
Forte Biosciences upgraded to Buy from Neutral at Chardan
  • 29
    Oct
FBRX Forte Biosciences
$29.43 /

-4.14 (-12.33%)

FBRX Forte Biosciences
$29.43 /

-4.14 (-12.33%)

Syndicate
Forte Biosciences $30M Spot Secondary re-offered at $28.50 » 16:38
10/28/20
10/28
16:38
10/28/20
16:38
FBRX

Forte Biosciences

$29.43 /

-4.14 (-12.33%)

Ladenburg, Truist and…

Ladenburg, Truist and Chardan are acting as joint book running managers for the offering.

ShowHide Related Items >><<
FBRX Forte Biosciences
$29.43 /

-4.14 (-12.33%)

FBRX Forte Biosciences
$29.43 /

-4.14 (-12.33%)

09/24/20 Chardan
Forte Biosciences price target raised to $110 from $60 at Chardan
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
09/10/20 Chardan
Forte Biosciences price target raised to $60 from $45 at Chardan
08/28/20 Chardan
Forte Biosciences upgraded to Buy from Neutral at Chardan
FBRX Forte Biosciences
$29.43 /

-4.14 (-12.33%)

FBRX Forte Biosciences
$29.43 /

-4.14 (-12.33%)

Syndicate
Forte Biosciences files to sell common stock, no amount given » 16:09
10/28/20
10/28
16:09
10/28/20
16:09
FBRX

Forte Biosciences

$29.50 /

-4.07 (-12.12%)

Ladenburg Thalmann,…

Ladenburg Thalmann, Truist Securities and Chardan are acting as joint book-running managers for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as a co-manager for the offering.

ShowHide Related Items >><<
FBRX Forte Biosciences
$29.50 /

-4.07 (-12.12%)

FBRX Forte Biosciences
$29.50 /

-4.07 (-12.12%)

09/24/20 Chardan
Forte Biosciences price target raised to $110 from $60 at Chardan
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
09/10/20 Chardan
Forte Biosciences price target raised to $60 from $45 at Chardan
08/28/20 Chardan
Forte Biosciences upgraded to Buy from Neutral at Chardan
FBRX Forte Biosciences
$29.50 /

-4.07 (-12.12%)

FBRX Forte Biosciences
$29.50 /

-4.07 (-12.12%)

Hot Stocks
Forte Biosciences receives fast track designation for FB-401 from FDA » 08:33
10/26/20
10/26
08:33
10/26/20
08:33
FBRX

Forte Biosciences

$35.37 /

+1.92 (+5.74%)

Forte Biosciences…

Forte Biosciences announced that the FDA has granted fast track designation to FB-401 for the treatment of atopic dermatitis. FB-401 is a topically applied live biotherapeutic consisting of specifically selected strains of commensal Roseomonas mucosa and has demonstrated excellent tolerability and significant improvement in atopic dermatitis disease activity in both adults and children in a Phase 1/2a trial which was recently published in Science Translational Medicine. Forte is currently enrolling a trial of FB-401 in atopic dermatitis.

ShowHide Related Items >><<
FBRX Forte Biosciences
$35.37 /

+1.92 (+5.74%)

FBRX Forte Biosciences
$35.37 /

+1.92 (+5.74%)

09/24/20 Chardan
Forte Biosciences price target raised to $110 from $60 at Chardan
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
09/10/20 Chardan
Forte Biosciences price target raised to $60 from $45 at Chardan
08/28/20 Chardan
Forte Biosciences upgraded to Buy from Neutral at Chardan
FBRX Forte Biosciences
$35.37 /

+1.92 (+5.74%)

FBRX Forte Biosciences
$35.37 /

+1.92 (+5.74%)

Hot Stocks
Forte Biosciences announces first patient dosing in atopic dermatitis trial » 09:04
09/29/20
09/29
09:04
09/29/20
09:04
FBRX

Forte Biosciences

$50.33 /

+1.39 (+2.84%)

Forte Biosciences…

Forte Biosciences announced that the first patient has been dosed in the clinical trial of FB-401 for the treatment of atopic dermatitis. The multi-center, placebo controlled clinical trial of FB-401 is expected to enroll approximately 124 pediatric, adolescent and adult subjects aged 2 years of age and older with atopic dermatitis,AD. The primary endpoint of the trial is EASI-50, which is a measure of the proportion of patients that achieve at least a 50% improvement in the atopic dermatitis disease burden as measured by the Eczema Area and Severity Index, EASI. FB-401 is a topically applied live biotherapeutic consisting of specifically selected strains of commensal Roseomonas mucosa and has demonstrated excellent tolerability and significant improvement in atopic dermatitis disease activity in both adults and children in a Phase 1/2a trial which was recently published in Science Translational Medicine. "We are very excited to be initiating this clinical study," said Paul Wagner, Ph.D., Chief Executive Officer of Forte Biosciences. "FB-401 has the potential to address a significant unmet need for pediatric and adult patients suffering from atopic dermatitis. Children, in particular have limited treatment options and account for the majority of the approximately 17 million AD patients in the U.S. alone." For additional information about the trial, see ClinicalTrials.gov using identifier NCT04504279.

ShowHide Related Items >><<
FBRX Forte Biosciences
$50.33 /

+1.39 (+2.84%)

FBRX Forte Biosciences
$50.33 /

+1.39 (+2.84%)

09/24/20 Chardan
Forte Biosciences price target raised to $110 from $60 at Chardan
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
09/10/20 Chardan
Forte Biosciences price target raised to $60 from $45 at Chardan
08/28/20 Chardan
Forte Biosciences upgraded to Buy from Neutral at Chardan
FBRX Forte Biosciences
$50.33 /

+1.39 (+2.84%)

FBRX Forte Biosciences
$50.33 /

+1.39 (+2.84%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.